Skip to main content
Figure 3 | Diagnostic Pathology

Figure 3

From: Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer

Figure 3

Associations between MSI screening status, beta-catenin expression and survival in stage III disease stratified according to adjuvant therapy. Kaplan-Meier analysis of colorectal cancer specific survival according to (A) MSI screening status and no adjuvant treatment (logrank p = 0.415), (B) Beta-catenin score and no adjuvant treatment (logrank p = 0.783), (C) MSI screening status and adjuvant FLV (5-fluorouracil + leucovorin ) (logrank p = 0.251), (D) Beta-catenin score and adjuvant FLV (logrank p = 0.927), (E) MSI screening status and adjuvant FLOX (5-fluorouracil + leucovorin + oxaliplatin ) (logrank p = 0.871) and (F) Beta-catenin score and adjuvant FLOX (logrank p = 0.336).

Back to article page